572 related articles for article (PubMed ID: 28362135)
1. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
[TBL] [Abstract][Full Text] [Related]
2. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
[TBL] [Abstract][Full Text] [Related]
4. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.
Estívariz CF; Anand A; Gary HE; Rahman M; Islam J; Bari TI; Wassilak SG; Chu SY; Weldon WC; Pallansch MA; Heffelfinger JD; Luby SP; Zaman K
Lancet Infect Dis; 2015 Aug; 15(8):898-904. PubMed ID: 26093980
[TBL] [Abstract][Full Text] [Related]
8.
Zhao T; Mo Z; Ying Z; Huang T; Che Y; Li G; Yang X; Sun M; Jiang L; Shi L; Ye H; Zhao Z; Liu X; Li J; Li Y; Li R; Jiang R; Wang J; Fu Y; Ma R; Shi H; Yang H; Li C; Yang J; Li Q
Ann Transl Med; 2021 Feb; 9(3):253. PubMed ID: 33708880
[TBL] [Abstract][Full Text] [Related]
9. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey.
Xu J; Wang Q; Kuang S; Rong R; Zhang Y; Fu X; Tang W
Hum Vaccin Immunother; 2021 Jul; 17(7):2125-2131. PubMed ID: 33759702
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
[TBL] [Abstract][Full Text] [Related]
12. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
Ye H; Huang T; Ying ZF; Li GL; Che YC; Zhao ZM; Wang JF; Yang XL; Shi L; Jiang RJ; Liu XC; Mo ZJ; Li CG; Yang JS
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jan; 52(1):43-49. PubMed ID: 29334707
[No Abstract] [Full Text] [Related]
13. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
Bandyopadhyay AS; Modlin JF; Wenger J; Gast C
Clin Infect Dis; 2018 Oct; 67(suppl_1):S35-S41. PubMed ID: 30376081
[TBL] [Abstract][Full Text] [Related]
15. Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine.
Zhao T; Li J; Shi H; Ye H; Ma R; Fu Y; Liu X; Li G; Yang X; Zhao Z; Yang J
Hum Vaccin Immunother; 2021 Aug; 17(8):2560-2567. PubMed ID: 33848232
[TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity and lot-to-lot consistency of a new Bivalent Oral Polio Vaccine (bOPV) in healthy Infants: Results of a Phase III, observer blind, randomized, controlled clinical study.
Zaman K; Kingma R; Yunus M; van Straaten I; Mekkes D; Bouwstra X; Gunale B; Kulkarni PS
Vaccine; 2019 Jul; 37(31):4275-4280. PubMed ID: 31235374
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan.
Saleem AF; Mach O; Yousafzai MT; Khan A; Weldon WC; Steven Oberste M; Zaidi SS; Alam MM; Quadri F; Sutter RW; Zaidi AKM
J Infect Dis; 2018 Jan; 217(3):443-450. PubMed ID: 29126173
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China.
Yan S; Chen H; Zhang Z; Chang S; Xiao Y; Luo L; Zhang Z; Sun L; Chen X; Yang Y; Shi X; Guo Y; Sun Y; Li H; Li N; Han S; Ma M; Yang X
Vaccine; 2020 Sep; 38(40):6274-6279. PubMed ID: 32747216
[TBL] [Abstract][Full Text] [Related]
19. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
Immunization Systems Management Group of the Global Polio Eradication Initiative
MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
[TBL] [Abstract][Full Text] [Related]
20. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
Anand A; Zaman K; Estívariz CF; Yunus M; Gary HE; Weldon WC; Bari TI; Steven Oberste M; Wassilak SG; Luby SP; Heffelfinger JD; Pallansch MA
Vaccine; 2015 Nov; 33(48):6816-22. PubMed ID: 26476367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
